Deeptech Startup En Carta Diagnostics Raises €5M to Scale At-Home Molecular Testing

Paris, France — 10 July, 2026. En Carta Diagnostics, a deep-tech start-up developing a new generation of molecular diagnostics for use at home, today announces a first closing of €5 million in financing.

This closing includes €3 million in equity led by Blue Forest Ventures with participation from Ring Capital and existing investors CentraleSupélec Venture, 50 Partners Health, and a group of business angels. It also includes €2 million in non-dilutive from Bpifrance and other partners. 

The proceeds will be used to advance three strategic priorities: 
-  Regulatory certification of its molecular testing solutions in Europe and the US, supported by its recent FDA Breakthrough Device Designation and progression along an accelerated regulatory pathway 
- Industrialization at scale, through a fabless model in partnership with Circum Medical to produce the hardware of the product, enabling cost-efficient, high-volume manufacturing 
- Commercial launch and market expansion, starting with early Lyme disease detection and followed by additional applications such as STI screening

Strong momentum driven by clinical, regulatory and commercial milestones

En Carta has achieved its first-in-human and is running two clinical trials for its flagship product for the early detection of Lyme: in Boston (USA) and in Bialystok (Poland). 

In January 2026, it received the FDA Breakthrough Device Designation, a status reserved for breakthrough technologies with strong scientific foundations and a clear response to a critical unmet medical need. This designation grants En Carta an accelerated regulatory pathway to the US market.

​

Several months later, the company signed a co-development and commercialization agreement with AAZ, the French pioneer in self-tests and rapid diagnostic tests. The agreement represents a €13 million commercial partnership, combining financial commitment and clinical development.  The objective is to market a new generation of rapid molecular tests for chlamydia and gonorrhea, in Europe, with committed volumes of several million units over five years.

Addressing critical gaps in early disease detection

The company is addressing Lyme disease, the most prevalent vector-borne disease in the Northern Hemisphere, with 1.2 million cases annually. This disease is caused by Borrelia bacteria, transmitted to humans through tick bites, and its incidence is increasing alarmingly at 22.5% per year according to the CDC (Centers for Disease Control and Prevention). Despite this growing threat, existing diagnostic tools cannot detect the infection until weeks after a tick bite, precisely when patients and clinicians need answers most.

En Carta was founded to solve exactly that problem, developing a molecular diagnostic product as simple to use as a rapid test, as precise as a laboratory PCR, and delivering a result in 30 minutes, at home.

“From FDA Breakthrough Designation to a €13M commercial partnership, and now €5M in financing, En Carta is delivering. Our next milestone is getting our two products, a rapid molecular diagnostic for Borrelia, the bacteria responsible for Lyme disease, and an STI screening test, into the hands of patients and clinicians across Europe and the US.  
This first closing brings us closer to our mission of transforming access to testing. By enabling patients to perform reliable molecular tests wherever they are, we can support earlier diagnosis, improve patient outcomes, and help relieve pressure on healthcare systems.”
Guillaume Horreard, Co-founder and CEO, En Carta Diagnostics

En Carta’s technology is a rapid Point-of-Need molecular diagnostic platform, in an affordable cassette format, exhibiting high precision through a technology underpinned by more than ten years of intensive research. It uses aptamers, capable of binding with high affinity and specificity to a predetermined target. This ‘signature’ can be programmed to detect any genetic, pathogenic or veterinary indication, opening an extensive range of applications.

​

With strong regulatory, commercial, and financial foundations in place, En Carta Diagnostics is now focused on bringing its technology to market at scale. Starting with early Lyme disease detection and expanding into STI screening, the company is building a new generation of diagnostic solutions designed to deliver fast, reliable results wherever patients are.

​

“Improving access to fast, reliable diagnosis is essential to delivering better healthcare outcomes”. En Carta Diagnostics’ technology has the potential to significantly enhance early detection and bring high-quality molecular testing closer to patients. This aligns fully with our mission to support innovations that improve care pathways and patient access.”

Max Narr, Co-Founder and General Partner, Blue Forest Ventures